NPPB and hydrops fetalis: The DELIVER trial studies the effects of dapagliflozin in patients with HF with preserved ejection fraction (with "EF >40%, structural heart disease, increased NT-pro BNP levels, NYHA II-IV") on cardiovascular death or HF events.